Vickie S. Reed - 14 Jan 2022 Form 4 Insider Report for Mirati Therapeutics, Inc.

Role: SVP, Chief Accounting Officer
Signature: /s/ Elizabeth Gelfand, Attorney in Fact
Issuer symbol: N/A
Transactions as of: 14 Jan 2022
Net transactions value: -$64,217
Form type: 4
Filing time: 18 Jan 2022, 19:34:06 UTC
Previous filing: 07 Jan 2022
Next filing: 28 Apr 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRTX	Common Stock	Award	$0	+5,377	+51%	$0.000000	15,902	14 Jan 2022	Direct	F1
transaction	MRTX	Common Stock	Sale	$64,217	-533	-3.4%	$120.48	15,369	18 Jan 2022	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MRTX	Employee Stock Option (Right to Buy)	Award	$0	+8,910		$0.000000	8,910	14 Jan 2022	Common Stock	8,910	$124.31	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Grant of Restricted Stock Units (RSUs). Shares will vest 25% annually on the anniversary of the grant date until fully vested.
F2	Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 15, 2021.
F3	The price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $120.2091 to $120.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
F4	25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.